Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The will be plenty of class action advertisements .
They are all fluff.
I’m here for the truth. Skepticism is part of the package. I don’t know the first thing about Jennifer, so she shouldn’t take it personally. But it looks like she got the scoop. And it’s amazing news.
Well, maybe miracles do happen, and we’ll be dancing in the street on Monday.
No. I’m referring to jbourke.
It’s a little shocking how quick people are to accept an unsubstantiated claim from someone who has literally never posted on this board before.
Another amazing day! CYDY is starting to string them together. Could we see $5.00 by EOW?
Goooooood moooorning, Cytodyyyyyyyn!
Another great day to end a great week for CYDY. The future is bright!
LAUGHING
LAUGHING
LAUGHING
LAUGHING
LAUGHING
LAUGHING
Fantastic news from CYDY. And savvy investors responded by snapping up shares en masse. The future is bright!
There is absolutely nothing wrong with what you are doing.
I think that’s the billion dollar question.
I think the answer is no.
I think that means we will get an EUA.
And I think the share price will reflect that.
When the shares were authorized, people screamed “dilution”. When the same shares were assigned, people screamed “dilution”. When the obligations for those same shares are renewed, people scream “dilution”.
I want this drug!
And that’s a fact!
This post needs to be stickied.
It will get more than cut in half if the data is bad.
But the price will triple on good data.
It looks to me like the price to get in before data is ~$6.
Time is running out to place your bets.
I think the data will be GOOD!
Ah, ye olde “too good to be true” argument. They’ve been using that one since we were in the .30s. The smart money could’ve made a 20-30x return from those levels — or even more, since we were offering warrants at that price! But they won’t be buying until the writing is on the wall. Not too smart if you ask me!
Keep up the good work. Wouldn’t it be something if monsters were finally held to account!
The moment of truth is almost here!
That’s one thing everyone can agree on: data is coming, for better or worse.
For my part, I hope the shorts and fear-mongers are able to push the price down to the mid-$5s one last time before the weekend, so I can add to my already-oversized position.
ALL signs indicate that the trial will be a massive success.
I couldn’t be more excited!
LAUGHING!
I can’t speak for you, but I’m pretty excited. This is the investment of a lifetime!
Anyone who wants to dump at $7 will have an opportunity tomorrow. But they may be better off dumping at $8 on Tuesday or $10 at the end of the week. For my part, I won’t be dumping any until at least the $30s. I shouldn’t have too much longer to wait.
Exactly. We’ve been climbing for months. We’re deep in the green on every time scale except the weekly (which is only marginally down). If this is a pump and dump, the pump hasn’t even begun!
Black Ops has been telling this story for
Months:
https://www.zerohedge.com/markets/naked-short-selling-truth-much-worse-you-have-been-told
Well, they’ve moved on from *this* message board, for obvious reasons.
Gonna be a green close.
More good advice. The pumping is getting out of hand.
Such great advice about debt. I have always shunned it.
We’re up 28% today on massive volume! The market is DEFINITELY interested! Lol
LAUGHING!
LAUGHING!
LAUGHING!
LAUGHING!
When leronlimab is finally approved, all the pain will be transferred from the innocent victims of COVID-19 to the grotesqueries who fought to keep this medicine from those who needed it.
Just thinking about how they are going to suffer gives me a tingly feeling down my leg.
TBD
Hey, what happened to all the bears?
Fantastic news!
Bulls be knock knock knocking in heaven’s door.
Anyone betting that Leronlimab is “saline” will soon discover otherwise!
LAUGHING
LAUGHING
LAUGHING
CYDY Shorts are packing it in.
Gonna be a crazy strong close!
LAUGHING.
From a technical standpoint, the CYDY chart is absolutely mouthwatering.
I think we could hit $6.50 tomorrow.
Anyone foolish enough to have held on to their ill-conceived short positions are about to get a special lesson from the School of Hard Knocks.
LAUGHING.
CYDY longs are LAUGHING
Excellent response!
A great response by CTMedic to some of the misinformation out there!
—————————-
We seem to have a disagreement on very basic facts regarding clinical trials.
This is quite perplexing to me.
Quote:
The Cytodyn trial would not have been necessarily stopped if there was no separation from Placebo in terms of efficacy. It is equally hard to stop early for inefficacy than it is to stop early for efficacy.
Stopping the trial for lack of efficacy is a key responsibility of a DSMB. Please recall, the DSMB is selected by Cytodyn, and in addition to protecting patients from harm, also acts to halt trials that will not succeed, or modify them sufficiently to have a likely chance of success (witness 56% increase in study population of Humanigen's lenzilumab trial)
"Statement—NIH-Sponsored ACTIV-3 Trial Closes LY-CoV555 Sub-Study
October 26, 2020
The ACTIV-3 clinical trial evaluating the investigational monoclonal antibody LY-CoV555 in hospitalized patients with COVID-19 will not enroll more participants into this sub-study following a recommendation from the independent Data and Safety Monitoring Board (DSMB). The trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health."
Quote:
You need quite a lot of patients and, as I already wrote, my analysis is that the Cytodyn trial is under powered, it doesn't have enough patients to prove any hypothetical effect (which anyway I think doesn't exist). The reason it is underpowered is because I believe Cytodyn designed the trial back in March based on much higher mortality assumptions. That's what I found out reverse-engineering their trial parameters with a statistical model
You believe this trial is underpowered based on your "reverse-engineering" with a statistical model. I apologize in advance, but this does not explain how you determined this or support what you state you "believe".
The primary endpoint is 28 day mortality. With 87 known deaths in the trial, a reduction of 35% (47 leronlimab arm deaths, 36 placebo arm) has a P=0.036. Not that any of us want more to die of covid, but the discussion at 50%/195 interim trial analysis of death approaching 50 excited Cytodyn shareholders because this level of mortality is exactly what is required to leave a reasonable opportunity for leronlimab to demonstrate statistically and clinically significant decrease in mortality.
The DSMC apparently agreed, as:
Quote:
CytoDyn Receives Positive DSMC Recommendation after Interim Analysis for Leronlimab Phase 2b/3 COVID-19 Registrational Trial
DSMC recommends CytoDyn continue the study as planned, with the protocol defined sample size and power to achieve the primary endpoint
You stated:
Quote:
- The more deaths, the lower chance to have a positive outcome.
This is backwards IMO and appears to be the reverse of what you just argued. The higher the mortality rate, the more opportunity for leronlimab to demonstrate efficacy. If no one died, no opportunity to decrease mortality. If 100% of placebo patients died, larger opportunity for leronlimab to demonstrate reduction in mortality.
Quote:
Because Leronlimab had 2/3rd of patients and they already are, across arms, in the top-range of ALL worldwide studies of SOC mortality for Severe+Critical patients. More deaths means Leronlimab is not pulling down the mortality as it is supposed to
We had discussed and it remains a fact, that until unblinding, no one knows the distribution of deaths. That is the important issue to be determined.
We do know that the mortality of critical covid patients is higher than that of the general hospitalized patient population. How high is a GUESS. Remember though, CD12 enrolled patients with just far few exclusions that any other trial of which I am aware. (If you are aware of trials with such a critical trial population, I would be very thankful should you choose to share your knowledge.)
Do not intubate
Do not resuscitate
Not eligible for renal dialsyis
On high dose vasopressors for more than 48 hours.
Allergy to leronlimab
Pregnancy
-
Quote:
There is no fact to support this: "They know it is very favourable to the drug and that's the reason they gave out that number in the last conference call.". If I were them I would have avoided disclosing that number if I could have done so because this is a bad number knowing SOC has low mortality and getting lower every month. Hence I believe they only disclosed it because they had to for obvious legal reasons (material piece of information for shareholders, hiding it would be a SEC crime).
This is your assessment of Cytodyn's approach to releasing information. We each have our own approach. Very likely holding information close to the vest would induce fewer emotional responses, positive or negative. I would behave differently if I made these decisions, but neither of us is running Cytdoyn and none of this impacts the trial results.
Quote:
- Billing codes have no relationship with future FDA approvals. Same for open label cohorts.
There have been a number of rational assessments (I apologize for not having the link) that showed a very strong correlation between ICD-10 code generation and approval. It is only a correlation and is not 100% predictive, so I agree, you are correct, we should not base investing approach on the existence of these codes.
Quote:
- For CD10 you wrote a post-hoc rationale but the ex-ante rationale (that I didn't believe in) was exactly the opposite. It said that it would be a tremendous success. My point about Leronlimab to the contrary hasn't changed before and after CD10: I believe Leronlimab acts like saline against COVID, and in fact against most diseases. Whether it's mild, moderate, severe or critical COVID, same failure against SOC.
CD10 results indicated marked reduction in SAEs and worsening clinical condition. The trial was small, the FDA shrugged its shoulders at the mild/moderate population. No EUA or approval. Again you are correct.
But, you may "believe leronlimab acts like saline against Covid", but your belief is not supported by multiple accounts, in peer-reviewed articles, of the ability of leronlimab to reverse immune dysfunction in severe viral illness.
Remember, this ability is not dependent on acting directly against Covid. Its efficacy is not pathogen dependent, but rather leronlimab through CCR5 antagonism block monocyte (macrophage) trafficking and lymphocyte hyperactivation/exhaustion, with a resultant marked diminution of the cytokine storm and restoration of anti-viral activity, through resumption of granzyme production (really cool serine proteases that lyse ("kill") virally infected cells. Go killer T cells!)
Quote:
Plus, SOC has been greatly improving, so I view this battle that was already doomed as hopeless.
We are all pleased that the SOC (standard of care) has improved. You may "view this battle that was already doomed as hopeless", but that is your perspective only.
Again, CD12 trial is complete. Amarex working diligently to determine the trial results.
Results will be out eventually, though I HOPE and EXPECT very soon. My hope and expectation may be optimistic, but eventually trial results will resolve these open issues.
Patience.
“Based on the information publicly available as of November 2020, 44 antibody therapeutics are in late-stage clinical studies for non-cancer indications, including 6 for COVID-19, and marketing applications for at least 6 (leronlimab, tezepelumab, faricimab, ligelizumab, garetosmab, and fasinumab) are planned in 2021.”
https://pubmed.ncbi.nlm.nih.gov/33459118/